

Innovative Strategies on the Use of Long-Acting Antiretroviral Therapy

Implementation at JPS

- First patient received Cabenuva™ in August 2021
- Led by clinical pharmacist and now with assistance with a dedicated nurse (THANK YOU Tarrant County AA!!)
- 165 active patients
- 18 discontinuations
 - Mostly due to relocating (n=7)
 - Second most common reason is injection site reactions (n=5)
 - Other reasons include death unrelated to therapy (n=2), adherence issues (n=2), personal preference (n=1), and virologic failure (n=1)



Use of Cabenuva™ in Viremic Patients at JPS

- Medical providers were informed to refer patients in 10/2024
- Recruited 4 patients so far
 - Recently diagnosed and struggles with her diagnosis
 - Recently released from prison with a long history of non-adherence
 - Diagnosed as a youth and struggles with depression
 - French-speaking patient with privacy concerns



Partnership with Albertsons/Tom Thumb Pharmacies

- Patients now have the option to have their injections administered at a local Albertsons or Tom Thumb
- First clinic in the country to enroll in this pilot program
- 28 patients are enrolled
- Benefits include:
 - Appointment flexibility (i.e., open in the evenings and weekends)
 - Proximity
 - Going to a non-HIV clinic

